Solid Dispersion Preparation and Characterization Service
Solid Dispersion Preparation and Characterization Service
Services
Online Inquiry

Solid Dispersion Preparation and Characterization Service

Amorphous Solid Dispersion

Transform poorly water-soluble crystalline APIs into amorphous solid dispersions to dramatically enhance dissolution and bioavailability for early-stage development.

  • Carrier and drug-to-carrier ratio screening tailored to your API
  • Spray drying, hot-melt extrusion, or solvent evaporation preparation
  • Solid-state characterization by XRD, DSC, TGA, SEM, and FT-IR
  • In vitro dissolution testing and accelerated stability assessment
  • Comprehensive report guiding downstream formulation decisions

Is your API poorly soluble?

Amorphous solid dispersions increase apparent solubility and dissolution rate by converting crystalline drug into a high-energy amorphous state within a hydrophilic carrier.

  • Expert selection of polymer or silica carriers
  • Techniques: spray drying, hot-melt extrusion, solvent evaporation
  • Full characterization to confirm amorphization and stability
  • Project-scoped formulation screening to optimize performance
Amorphous
Bioavailable
Stable
Approach

Our Solid Dispersion Development Workflow

We combine rational carrier selection, robust preparation methods, and comprehensive solid-state characterization to deliver a formulation-ready amorphous dispersion for your poorly soluble compound.

Core Dispersion Development

Systematic screening of drug–carrier combinations and preparation techniques to produce stable amorphous dispersions.

  • API physicochemical evaluation and carrier compatibility screening
  • Drug-to-carrier ratio optimization using design of experiments
  • Preparation via spray drying, hot-melt extrusion, or solvent evaporation

Integrated Biopharmaceutical Assessment

Coupling solid dispersion characterization with in vitro release and stability data to bridge formulation performance to in vivo outcomes.

  • Dissolution testing under biorelevant conditions
  • Accelerated and long-term stability monitoring
  • Data packaged for preclinical formulation decisions

Analytical Rigor

X-ray diffraction (XRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), scanning electron microscopy (SEM), and FT-IR confirm amorphization, molecular interactions, and thermal behavior.

Stability-First Design

We evaluate physical stability under stress (temperature, humidity) and recommend appropriate storage conditions to minimize recrystallization risk.

Scalability Insight

Process parameters are documented to support scale-up feasibility and technology transfer to manufacturing partners.

Deliverables

What You Receive

Every solid dispersion project delivers a complete data package and actionable interpretation tailored to your development stage.

Data Deliverables

  • XRD diffractograms confirming amorphous halo pattern
  • DSC/TGA thermograms with glass transition temperature
  • SEM images illustrating particle morphology
  • FT-IR spectra highlighting drug–carrier interactions
  • Dissolution profiles under sink and non-sink conditions

Reporting & Support

  • Comprehensive formulation development report with methods and results
  • Stability assessment under accelerated conditions
  • Oral project consultation to discuss findings and next steps
  • Raw data and instrument files for regulatory reference
Service Scope

Customizable Project Parameters

Each engagement is scoped case-by-case around your API, desired outcome, and development timeline. Below are typical parameters we address during consultation.

ParameterTypical Project Scope
API Quantity RequiredSubject to API solubility and planned screening size; 100–500 mg typical for initial screening
Carrier LibrarySelection from cellulosic polymers, vinyl polymers, and mesoporous silicas based on API properties
Drug-to-Carrier RatiosMultiple ratios screened (e.g., 1:1, 1:2, 1:3 w/w) to identify optimal formulation
Preparation MethodsSpray drying, hot-melt extrusion, solvent evaporation; methods chosen per API thermal stability
Solid-State CharacterizationXRD, DSC, TGA, SEM, FT-IR – all techniques applied per sample
In Vitro DissolutionUSP apparatus II or IV with biorelevant media; time points as scoped
Stability Study ConditionsAccelerated (40°C/ performance scoped per project RH) and/or long-term storage; duration scoped per project
Reporting FormatPDF report with data tables, chromatograms, and expert interpretation
How It Works

Solid Dispersion Development Process

Our streamlined workflow moves from API evaluation through to a characterized dispersion ready for early-stage formulation.

API & Carrier Assessment

We evaluate your API's physicochemical properties (melting point, solubility, thermal stability) and select a compatible polymer or silica carrier based on solubility parameters and molecular interactions.

Drug-to-Carrier Ratio Screening

A range of drug-to-carrier ratios is prepared using a small-scale method to identify the formulation that maximizes amorphization and dissolution while maintaining physical stability.

Solid Dispersion Preparation

The optimized composition is scaled up using spray drying, hot-melt extrusion, or solvent evaporation to produce a homogenous amorphous dispersion. Process parameters are documented for reproducibility.

Solid-State Characterization

The dispersion is analyzed by XRD (amorphous halo), DSC/TGA (glass transition, thermal events), SEM (morphology), and FT-IR (molecular interactions) to confirm amorphization and carrier compatibility.

Dissolution & Stability Evaluation

In vitro dissolution testing under biorelevant conditions quantifies the improved release rate. Accelerated stability studies assess the risk of recrystallization and guide storage recommendations.

Applications

Where Solid Dispersions Deliver Value

Our solid dispersion service supports a range of development needs for poorly soluble compounds.

Accelerate Preclinical Formulation

Solid dispersions provide a simple, scalable formulation approach for early toxicology and PK studies, enabling evaluation of full therapeutic potential.

  • Suitable for first-in-animal PK and toxicology studies
  • Reduces time spent on conventional solubility enhancement

Overcome Poor Oral Absorption

By converting crystalline API to amorphous form in a hydrophilic carrier, solid dispersions can increase oral bioavailability by several fold.

  • Increase in AUC and Cmax demonstrated in multiple case studies
  • Applicable to BCS Class II and IV compounds

Stabilize Amorphous Form

Careful carrier selection and characterization reduces recrystallization risk, maintaining the enhanced solubility over shelf life.

  • Accelerated stability testing under ICH conditions
  • Identification of optimal storage conditions
FAQ

Solid Dispersion Service – Frequently Asked Questions

Answers to common questions about our approach, deliverables, and applicability to your development program.

  • An amorphous solid dispersion is a formulation in which a poorly water-soluble crystalline drug is dispersed at the molecular level in an inert hydrophilic carrier (polymer or silica). This eliminates the crystal lattice, creating a high-energy amorphous state that significantly increases apparent solubility and dissolution rate.

  • We evaluate your API's physicochemical properties (melting point, solubility parameters, thermal stability) and screen candidate carriers from our library of cellulosic polymers, vinyl polymers, and mesoporous silicas. The selection is optimized through drug-to-carrier ratio screening and compatibility analysis.

  • We offer spray drying, hot-melt extrusion, and solvent evaporation. The method is chosen based on your API's thermal and chemical stability, as well as the desired scalability. Each method is documented with process parameters to support future technology transfer.

  • Standard characterization includes X-ray diffraction (XRD) to confirm amorphization, differential scanning calorimetry (DSC) and thermogravimetric analysis (TGA) for thermal behavior, scanning electron microscopy (SEM) for morphology, and Fourier-transform infrared spectroscopy (FT-IR) for molecular interactions. Additional techniques can be added as scoped.

  • We conduct accelerated stability studies under elevated temperature and humidity (e.g., 40°C/ performance scoped per project RH) and monitor for recrystallization using XRD. Long-term stability can also be evaluated if required. Storage recommendations are provided based on the data.

  • Yes. For heat-sensitive compounds we typically use solvent evaporation or spray drying with mild processing conditions. For moisture-sensitive APIs, we can recommend carriers with low hygroscopicity and advise on handling conditions during and after preparation.

  • We supply comprehensive characterization data and dissolution profiles that serve as a foundation for downstream formulation development. Upon request, we can also interpret results and recommend next steps during a project consultation.

Scientific Literature

References

  1. Zhang F, Mao J, Tian G, et al. Preparation and Characterization of Furosemide Solid Dispersion with Enhanced Solubility and Bioavailability. AAPS PharmSciTech. 2022;23(1):65. View on PubMed
  2. Yu JY, Kim JA, Joung HJ, et al. Preparation and characterization of curcumin solid dispersion using HPMC. Journal of food science. 2020;85(11):3866-3873. View on PubMed
  3. Rayapolu RG, Yadav B, Apte SS, et al. Development of posaconazole nanocrystalline solid dispersion: preparation, characterization and in vivo evaluation. Pharmaceutical development and technology. 2024;29(5):530-540. View on PubMed
  4. Borde S, Paul SK, Chauhan H. Ternary solid dispersions: classification and formulation considerations. Drug development and industrial pharmacy. 2021;47(7):1011-1028. View on PubMed
  5. Zhang C, Li B, Bai Y, et al. Polymers Enhance Chlortetracycline Hydrochloride Solubility. International journal of molecular sciences. 2024;25(19). View on PubMed
  6. Onoda H, Inoue Y, Ezawa T, et al. Preparation and characterization of triamterene complex with ascorbic acid derivatives. Drug development and industrial pharmacy. 2020;46(12):2032-2040. View on PubMed

Please kindly note that our products and services are for research use only.